IL65328A - Pharmaceutical compositions comprising a calcium-antagonistic gallopamil or verapamil and their preparation - Google Patents

Pharmaceutical compositions comprising a calcium-antagonistic gallopamil or verapamil and their preparation

Info

Publication number
IL65328A
IL65328A IL65328A IL6532882A IL65328A IL 65328 A IL65328 A IL 65328A IL 65328 A IL65328 A IL 65328A IL 6532882 A IL6532882 A IL 6532882A IL 65328 A IL65328 A IL 65328A
Authority
IL
Israel
Prior art keywords
calcium
antagonistic
active compound
gallopamil
verapamil
Prior art date
Application number
IL65328A
Other languages
English (en)
Other versions
IL65328A0 (en
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6129505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL65328(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL65328A0 publication Critical patent/IL65328A0/xx
Publication of IL65328A publication Critical patent/IL65328A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL65328A 1981-04-07 1982-03-23 Pharmaceutical compositions comprising a calcium-antagonistic gallopamil or verapamil and their preparation IL65328A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813113901 DE3113901A1 (de) 1981-04-07 1981-04-07 Wirkstoffzubereitung zur oralen applikation

Publications (2)

Publication Number Publication Date
IL65328A0 IL65328A0 (en) 1982-05-31
IL65328A true IL65328A (en) 1985-06-30

Family

ID=6129505

Family Applications (1)

Application Number Title Priority Date Filing Date
IL65328A IL65328A (en) 1981-04-07 1982-03-23 Pharmaceutical compositions comprising a calcium-antagonistic gallopamil or verapamil and their preparation

Country Status (17)

Country Link
EP (1) EP0063266B1 (xx)
JP (1) JPS57175113A (xx)
AT (1) ATE14076T1 (xx)
AU (1) AU555093B2 (xx)
CA (1) CA1184497A (xx)
DE (2) DE3113901A1 (xx)
DK (1) DK157482A (xx)
ES (1) ES511208A0 (xx)
FI (1) FI821253L (xx)
GR (1) GR74770B (xx)
HU (1) HU186855B (xx)
IE (1) IE52985B1 (xx)
IL (1) IL65328A (xx)
NO (1) NO157204C (xx)
NZ (1) NZ200244A (xx)
PT (1) PT74705B (xx)
ZA (1) ZA822327B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681583A (en) * 1993-07-09 1997-10-28 Apr Applied Pharma Research Sa Multilayered controlled-release oral solid pharmaceutical forms

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
LU86077A1 (fr) * 1985-09-18 1987-04-02 Pharlyse Sa Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques
LU86099A1 (fr) * 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
DE3809764A1 (de) * 1988-03-23 1989-10-05 Knoll Ag Mischung aus alginaten und polyacrylaten und deren verwendung
US5230901A (en) * 1988-03-23 1993-07-27 Knoll Ag Sustained release tablet of a mixture of alginates and polyacrylates
WO1990000391A1 (de) * 1988-07-13 1990-01-25 Knoll Aktiengesellschaft Arzneimittel-depotform auf alginatbasis
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
DE3932378A1 (de) * 1989-09-28 1991-04-11 Knoll Ag Feste arzneiform mit hohem verapamil-gehalt
US5695781A (en) * 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE1467781A1 (de) * 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681583A (en) * 1993-07-09 1997-10-28 Apr Applied Pharma Research Sa Multilayered controlled-release oral solid pharmaceutical forms

Also Published As

Publication number Publication date
EP0063266A3 (en) 1983-05-04
DE3113901A1 (de) 1982-10-28
IE820812L (en) 1982-10-07
ZA822327B (en) 1983-03-30
IE52985B1 (en) 1988-04-27
AU555093B2 (en) 1986-09-11
DK157482A (da) 1982-10-08
GR74770B (xx) 1984-07-12
NZ200244A (en) 1984-08-24
ES8307496A1 (es) 1983-08-16
PT74705B (en) 1983-11-14
DE3264519D1 (en) 1985-08-08
AU8238482A (en) 1982-10-14
PT74705A (en) 1982-05-01
ES511208A0 (es) 1983-08-16
JPS57175113A (en) 1982-10-28
IL65328A0 (en) 1982-05-31
ATE14076T1 (de) 1985-07-15
FI821253A0 (fi) 1982-04-07
FI821253L (fi) 1982-10-08
NO157204B (no) 1987-11-02
NO821084L (no) 1982-10-08
EP0063266A2 (de) 1982-10-27
EP0063266B1 (de) 1985-07-03
HU186855B (en) 1985-10-28
CA1184497A (en) 1985-03-26
NO157204C (no) 1988-02-10

Similar Documents

Publication Publication Date Title
IL65328A0 (en) Pharmaceutical compositions comprising a calcium-antagonistic active compound and their preparation
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
FR2694004B1 (fr) Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
ATE38991T1 (de) In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
DE60022895D1 (de) Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
EP0136464A3 (en) Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
EP0271013A3 (en) Basic substituted phenyl acetonitriles, their preparation and medicaments containing them
ES2105923B1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
KR890004705A (ko) 항바이러스성 제제
CA2078869A1 (en) Pharmaceutical compositions containing ipriflavone, process for the preparation thereof and relative therapeutic use
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
ES475533A1 (es) Un metodo para la preparacion de formas racemicas y optica- mente activas de 2-(4-difenilil)-n-(dimetilamino-alquil)pro-pionamida
IL65787A (en) Antiviral pharmaceutical compositions containing alpha,alpha-dialkyl-adamantylamines
HUT70033A (en) Process for producing synergetic pharmaceutical composition containing calcium channel blocking agent and calcium compound or vitamin d
NZ214103A (en) Antimicrobial composition; synergistic mixture of maduramicin and nicarbazin
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
IL87867A (en) Preparation of pharmaceutical compositions containing a 2,6-diamino-3-phenyl-azo-pyridine derivative
KR910018026A (ko) α-페닐-α피리딜알칸산 유도체를 함유하는 배뇨장애증상 치료제
SE8304818L (sv) Medicin med magsarslekande, spasmolytisk och lokalanesteserande verkan
JPS57114517A (en) Antidiabetic agent
FR2567755B1 (fr) Nouveau medicament anti-tumoral contenant comme ingredient actif le triacetoxy-1,8,9 anthracene